Great find, thanks for all your fantastic work. Looks like the...

Great find, thanks for all your fantastic work. Looks like the assays are sorted.

Frontiers in Immunology will be publishing a special issue early next year entitled "Alternative Gene and Cell Therapies in Hyperinflammatory Diseases". It will contain alot of discussion about MSB's therapies. Here is the Editor's background note to the special issue:

"In autoimmune diseases or transplant rejection, an exacerbated response to the graft or the self-develop (sic). Another scenario of disproportionate immune response is the cytokine release syndrome (CRS), a systemic inflammatory response characterized by a sharp increase of proinflammatory cytokines triggered by factors such as infections, drugs, chimeric antigen receptor T cell (CAR-T) therapy in oncologic patients, or GvHD. There are over 150 rare inflammatory/autoimmune diseases, many of which are incurable and terminal. The standard treatment to prevent these hyper-immune responses is the use of immunosuppressive drugs or immunoglobulins, but they still do not provide a definitive solution and produce side effects that are decisive in the patient's clinical course. Those pathologies have wide variability, and different causative and pathogenic processes, making the current treatment strategies fall short of the expected complete remission." (emphasis added).

Approval for GvHD should be a watershed moment. It's bound to be written up in the special issue.